Two new risk prediction tools can identify patients with diabetes who are at high risk of blindness and amputation – two serious complications of diabetes, finds a study published in The BMJ this…
Uncategorized
Vision Medicines, Case Western enter licensing agreement for VM200 for Stargardt disease
Vision Medicines has entered into an exclusive worldwide licensing agreement with Case Western Reserve University for VM200, an oral small molecule drug candidate for the treatment of Stargardt disease, according to a press release. “We are enthusiastic about the potential for VM200 and have initiated investigational new drug application-enabling studies to advance VM200 into a phase 1/2 program for Stargardt disease in 2016,” Chris Varma, PhD, chairman and CEO of Vision Medicines, said in the release.
Lots of Finger-Pointing Over ACA Co-Op Failures
(MedPage Today) — Much blame directed at CMS for poor oversight
Uncategorized
Regeneron reports $1.1 billion in revenue in third quarter
Regeneron reported $1.1 billion in total revenue in the third quarter compared with $726 million in the same quarter of 2014, according to a press release. The increase was partially attributed to an increase in net profit from commercialization of Eyl…
Uncategorized
VIDEO: Speaker gives pearls for toric IOLS
NEW YORK — At OSN New York 2015, Elizabeth Yeu, MD, shares pearls for using toric IOLs for astigmatism correction.
The Retina Group of Washington Selects Modernizing Medicine’s EMA Ophthalmology® EMR System to Streamline Physician Workflow and Improve Patient Care
BOCA RATON, Fla.–(BUSINESS WIRE)–Modernizing Medicine announced today that The Retina Group of Washington has selected EMA Ophthalmology to replace its legacy EMR solution.